Fiscal Year Ending March 2026 Consolidated Financial Results Overview and Full-Year Outlook for March 2027

Overview of Consolidated Results for Fiscal Year Ending March 2026

For the fiscal year ending March 2026, net sales reached ¥1,107.0 billion, a 1% increase YoY, but adjusted operating profit declined YoY to ¥143.3 billion, with an operating profit margin of 14.2%, down 4.7 points from the previous year. Net income attributable to owners of the parent was ¥24.8 billion, a decrease of 40% YoY. The primary factors for the profit margin decline include FDA-related import warnings and voluntary shipment suspensions (approximately ¥30 billion), headwinds from U.S. tariffs, poor sales mix, and one-time restructuring expenses. The Medical Systems (GIS) division performed well across North America, Europe, and Asia-Pacific, with sales of ¥210.1 billion, up 16% YoY (adjusted for currency effects, +10%). The Surgical Imaging Systems (SIS) division rebounded to growth following the resumption of urology product shipments, while respiratory and other therapy areas continue to be affected by shipment suspensions, but these impacts are under control.

2027 Year-End Performance Outlook and Growth Strategy

For the fiscal year ending March 2027, net sales are projected to be between ¥1.055 trillion and ¥1.076 trillion, with an adjusted operating profit margin of 15.2% to 16.7%. The foreign exchange-adjusted sales growth rate is expected to be 1.5% to 3.5%, with an operating profit margin improvement of 1.0pp to 2.5pp. In FY2027, Olympus plans to repurchase up to ¥60 billion of shares and aims to maintain a stable dividend of 30 yen per share. The company will continue investments in innovation, strengthen its GIS platform, and pursue strategic M&A, launching over ten new products. Olympus will shift from a dividend-centric shareholder return framework to a balanced approach of dividends and share buybacks, enhancing profitability and capital efficiency.